Cingulate partners with Indegene for ADHD therapy

B iopharmaceutical firm Cingulate and life sciences commercialisation firm Indegene have entered into a joint commercialisation deal for the former's attention-deficit/ hyperactivity disorder (ADHD) therapy CTx-1301 (dexmethylphenidate). The agreement is intended for providing commercial support for CTx-1301, after receiving the US Food and Drug Administration (FDA) approval. It covers cross-functional services through an omnichannel marketing approach designed for the management of the pre-commercial support during the Phase Ill clinical trials as well as the nationwide commercialisation of CTx-1301. The new investigational treatment CTx-1301 is being developed as a once-daily stimulant medication for the treatment of ADHD. cently, Cingulate commenced its first Phase Ill trial which has been designed for evaluating CTx-1301's fety and efficacy.